- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05312398
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio- Marker-driven Cetuximab-based Treatment Regimen Over 3 Treatment Lines in mCRC Patients With RAS/BRAF wt Tumors at Start of First Line
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Based on dynamic and longitudinal liquid biopsy assessment of RAS/BRAF status, that will be prospectively performed before each line of treatment, mCRC patients will be treated with cetuximab in combination with chemotherapy throughout three lines of therapy, as follows: FOLFIRI plus cetuximab (first line); FOLFOX plus cetuximab (second line); irinotecan plus cetuximab (third line) in case of RAS/BRAF WT at each time point of progression. If at progression after the first line, the liquid biopsy assessment indicates RAS and or BRAF mutant status, patients will be treated with FOLFOX plus bevacizumab as the second line of therapy. If at progression after the second line, the liquid biopsy assessment indicates RAS and or BRAF mutant status, patients will be treated with regorafenib or trifluridine-tipiracil (investigator's choice), as third line of therapy. Each treatment will be administered using standard doses and schedules until progression of disease or unacceptable toxicity.
This study will also evaluate the activity and efficacy of cetuximab re-introduction in combination with irinotecan as third line therapy in the concept of re-challenge for those patients that will be treated in second line with FOLFOX plus bevacizumab, having a RAS or BRAF mutant disease at the time of progression after FOLFIRI plus cetuximab first line treatment. A novel characteristic of this program is that the therapeutic algorithm will be defined at each treatment decision (first line, second line and third line) in a prospective fashion in each patient by liquid biopsy assessment of RAS/BRAF status
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Fortunato Ciardiello
- Phone Number: 0815666760
- Email: fortunato.ciardiello@unicampania.it
Study Contact Backup
- Name: Giulia Martini
- Phone Number: 0815666729
- Email: giulia.martini@unicampania.it
Study Locations
-
-
-
Napoli, Italy
- A.O.U. dell'Università degli studi della Campania "Luigi Vanvitelli"
-
Napoli, Italy
- Istituto Nazionale Tumori 'Fondazione G. Pascale'
-
-
AN
-
Ancona, AN, Italy
- A.O.U. Ospedali Riuniti
-
-
BA
-
Acquaviva Delle Fonti, BA, Italy
- Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli'
-
Bari, BA, Italy
- IRCCS Istituto Tumori 'Giovanni Paolo II'
-
Castellana Grotte, BA, Italy
- Ospedale IRCCS 'Saverio de Bellis'
-
-
BN
-
Benevento, BN, Italy
- Ospedale Sacro Cuore di Gesù - FATEBENEFRATELLI
-
-
BR
-
Brindisi, BR, Italy
- P.O. Antonio Perrino
-
-
CA
-
Monserrato, CA, Italy
- A.O.U. Cagliari - Presidio Policlinico D. Casula
-
-
CT
-
Catania, CT, Italy
- A.R.N.A.S. Garibaldi - P.O. Garibaldi-Nesima
-
-
CZ
-
Catanzaro, CZ, Italy
- A.O.U. Mater Domini
-
-
FG
-
San Giovanni Rotondo, FG, Italy
- Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza
-
-
LE
-
Lecce, LE, Italy
- P.O. 'Vito Fazzi'
-
Tricase, LE, Italy
- A.O. 'Pia Fondazione Cardinale G. Panico'
-
-
MI
-
Milano, MI, Italy
- Istituto Europeo di Oncologia
-
-
PA
-
Palermo, PA, Italy
- A.O.U. Policlinico 'P. Giaccone'
-
-
PD
-
Padova, PD, Italy
- Istituto Oncologico Veneto IRCCS
-
-
PI
-
Pisa, PI, Italy
- A.O.U. Pisana
-
-
PZ
-
Potenza, PZ, Italy
- A.O. San Carlo
-
-
RE
-
Reggio Emilia, RE, Italy
- A.U.S.L. - IRCCS di Reggio Emilia - P.O. Arcispedale S.Maria Nuova
-
-
RG
-
Ragusa, RG, Italy
- A.S.P. Ragusa - Ospedale Maria Paternò Arezzo
-
-
RM
-
Roma, RM, Italy
- A.O. San Camillo-Forlanini
-
Roma, RM, Italy
- Fondazione Policlinico Universitario 'Agostino Gemelli' IRCCS
-
-
TA
-
Statte, TA, Italy
- Ospedale San Giuseppe Moscati
-
-
TO
-
Torino, TO, Italy
- A.O. Ordine Mauriziano
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically proven diagnosis of colorectal adenocarcinoma
- Diagnosis of metastatic disease
- RAS and BRAF wild-type status of FFPE analysis of primary colorectal cancer and/or related metastasis
- Measurable disease according to Response Evaluation Criteria in Solid Tumors RECIST criteria, vers.1.1)
- Male or female patients ≥ 18 years of age
- ECOG Performance Status 0,1
Adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment as defined by the following parameters:
Bone marrow:
- Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
- Hemoglobin (Hgb) ≥ 9 g/dL
- Platelets ≥ 100 x 109/L
Liver function:
• Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and ALT (SGPT) ≤ 2.5 x ULN, except in patients with tumor involvement of the liver who must have AST and ALT ≤ 5 x ULN
Renal function:
• Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min
- If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment
- If female and of childbearing potential, or if male, agreement to use adequate contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double-barrier method), during the study and until at least 3 months after last dose of study treatment administration, based on the judgment of the Investigator or a designated associate
- Signed informed consent obtained before screening.
Exclusion Criteria:
- Any contraindication to the use of cetuximab, Irinotecan, 5-FU, oxaliplatin, folinic acid,bevacizumab, trifluridine-tipiracil, regorafenib
- Active uncontrolled infections, active disseminated intravascular coagulation or history of interstitial lung disease
- Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin cancer or in situ carcinoma of the cervix
- Pregnancy (exclusion to be ascertained by a beta hCG test)
- Breastfeeding
- Fertile women (<2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception•
- Myocardial infarction, unstable angina pectoris, balloon angioplasty (PTCA) with or without stenting within the past 12 months before inclusion in the study, Grade III or IV heart failure (NYHA classification)
- Cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin
- Medical or psychological impairments associated with restricted ability to give consent or not allowing conduct of the study
- Previous chemotherapy for the colorectal cancer with the exception of adjuvant treatment, completed at least 6 months before entering the study
- Participation in a clinical study or experimental drug treatment within 30 days prior to study inclusion or during participation in the study
- Known or clinically suspected brain metastases
- History of acute or subacute intestinal occlusion or chronic inflammatory bowel disease or chronic diarrhoea
- Severe, non-healing wounds, ulcers or bone fractures
- Uncontrolled hypertension
- Marked proteinuria (nephrotic syndrome)
- Known DPD deficiency (specific screening not required)
- Known history of alcohol or drug abuse
- A significant concomitant disease which, in the investigating physician's opinion, rules out the patient's participation in the study
- Absent or restricted legal capacity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm
This is an open-label phase II study investigating the efficacy and safety of a bio-marker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line. Based on dynamic and longitudinal liquid biopsy assessment of RAS/BRAF status, that will be prospectively performed before each line of treatment, mCRC patients will be treated with cetuximab in combination with chemotherapy throughout three lines of therapy, as follows:
If at progression after the first line or after the second line, the liquid biopsy assessment indicates RAS and or BRAF mutant status, patients will be treated with FOLFOX plus bevacizumab as second line of therapy, or with regorafenib or with trifluridine-tipiracil (investigator's choice) as third line therapy. |
I LINE: - FOLFIRI + cetuximab FOLFIRI: 200 mg L-folinic acid with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days. Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter II LINE: - FOLFOX + cetuximab FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days. Cetuximab: as I line THIRD LINE: - Irinotecan + cetuximab Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line
Other Names:
I LINE: - FOLFIRI + cetuximab FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days. Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter II LINE: - FOLFOX + cetuximab FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days. Cetuximab: as I line
Other Names:
III LINE: - Irinotecan + cetuximab Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RR
Time Frame: up to 59 months
|
Response rate (RR) for each line of treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in patients with RAS/BRAF wild type (WT) mCRCregimen over 3 treatment lines in patients with RAS/BRAF wild type (WT) mCRC at start of first line therapy
|
up to 59 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: from 8 weeks to 59 months (from the start of therapy until the first observation of disease progression or death due to any cause)
|
Progression free survival (PFS) for each line
|
from 8 weeks to 59 months (from the start of therapy until the first observation of disease progression or death due to any cause)
|
OS
Time Frame: up to 59 months
|
Overall Survival
|
up to 59 months
|
AE
Time Frame: from screening up to 59 months
|
Safety: Adverse events graded according NCI CTCAE v 5.0
|
from screening up to 59 months
|
EORTC Core Quality of Life questionnaire EORTC QLQ C30
Time Frame: At screening, for each line of therapy at Week 4, at Week 25 of treatment start and at progression
|
The EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions.
The questionnaire is composed of multi-item scales and single items
|
At screening, for each line of therapy at Week 4, at Week 25 of treatment start and at progression
|
DERMATOLOGY LIFE QUALITY INDEX (DLQI)
Time Frame: at screening, for each line of therapy at Week 4, at Week 25 of treatment start and at progression
|
The DLQI consists of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week.
|
at screening, for each line of therapy at Week 4, at Week 25 of treatment start and at progression
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Explorative objective: RR for each line of therapy
Time Frame: from screening up to 23 months
|
the response rates for each line of therapy of RAS/BRAF WT mCRC patients who will be treated in a continuum of care strategy with cetuximab across all three therapy lines
|
from screening up to 23 months
|
Exploratory objective: cumulative PFS
Time Frame: from screening up to 23 months
|
the cumulative progression free survivals of RAS/BRAF WT mCRC patients who will be treated in a continuum of care strategy with cetuximab across all three therapy lines
|
from screening up to 23 months
|
Explorative objective: overall survival
Time Frame: from screening up to 23 months
|
overall survival of RAS/BRAF WT mCRC patients who will be treated in a continuum of care strategy with cetuximab across all three therapy lines
|
from screening up to 23 months
|
Translational analyses using next generation sequencing (NGS) technologies
Time Frame: At day 1 of each line of therapy
|
Molecular profiles of tumor tissue and liquid biopsy samples (somatic mutations identified in tumor tissue by next generation sequencing) and surrogate markers of treatment activity (changes in molecular profile of liquid biopsies). Translational analyses of tumor biomarkers will be performed These include mutation in RAS, BRAF, PI3KCA; amplification of HER2, MET and loss of PTEN expression, all of which are implicated in resistance to anti-EGFR treatment. Moreover, 324 genes NGS panels will provide information regarding potential predictive and prognostic biomarkers of colorectal cancer disease. Fecal samples will be used for gut microbioma analysis, to understand how the composition of gut microbiome could influence treatment outcome and tolerability. |
At day 1 of each line of therapy
|
Collaborators and Investigators
Investigators
- Principal Investigator: Fortunato Ciardiello, A.O.U. dell'Università degli studi della Campania "Luigi Vanvitelli"
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAPRI2-MS062202-0123
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Adenocarcinoma
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal CarcinomaUnited States
-
Georgetown UniversityNational Cancer Institute (NCI); Mayo Clinic; Emory University; Indiana University and other collaboratorsTerminatedMetastatic Colorectal Cancer | Pancreatic Adenocarcinoma | Colorectal Adenocarcinoma | Metastatic Pancreatic CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Not yet recruitingMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8United States
-
Centre Hospitalier Universitaire DijonCompletedMetastatic Colorectal AdenocarcinomaFrance
-
Memorial Sloan Kettering Cancer CenterBayer; State University of New York - Downstate Medical Center; Queens Cancer...Active, not recruitingMetastatic Colorectal AdenocarcinomaUnited States
-
Hunan Cancer HospitalCompletedMetastatic Colorectal AdenocarcinomaChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
Clinical Trials on Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRecruitingHead and Neck Squamous Cell Carcinoma | Margin AssessmentNetherlands
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingColo-rectal Cancer | Capecitabine | CetuximabChina
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenTerminatedMetastatic Colorectal CancerNetherlands
-
Eben RosenthalNational Cancer Institute (NCI)TerminatedPancreatic AdenocarcinomaUnited States
-
HiberCell, Inc.TerminatedColorectal CancerUnited States, Puerto Rico, Germany, France
-
Merck KGaA, Darmstadt, GermanyCompletedPreviously Untreated Metastatic Colorectal CancerFrance, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCCompleted
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Poitiers University HospitalCompletedMetastatic Colon CancerFrance
-
Cliniques universitaires Saint-Luc- Université...Merck Sharp & Dohme LLC; Merck Serono International SACompleted